Microbioz India, October 2018

38

28

30

42

26

32 Cover Story

14

The edition includes an interview of Mr. Yogesh Mudras and discussion on multiple topics, Creativity and a constant quest to be innovative has been the backbone of the CPhI & P-MEC and the direct reason for its stupendous growth asked by Mr. Yogesh Mudras, Managing Director, UBM in recent interview with Microbioz India magazine for publication in October 2018 issue of the magazine.

Market research

22

Added to this, the current edition has a special featured article titled Telstar launches Lyogistics Smart R3, New automated inline vial management device able to reject, reintroduce and retrieve vials during loading / unloading process into pharmaceutical freeze-dryers By: Telstar

Product Launches

32

The edition also covers recent Healthcare news articles and product launches collected from worldwide sources to update the readers with the current trends in the industry

Apceth Biopharma Presents Positive Data Demonstrating Efficacy of apceth-201 in Preclinial Models of Acute GvHD

26

Munich, Germany, October 19, 2018 / B3C newswire / -apceth Biopharma GmbH, a company with the mission of improving patients’ lives with next generation cell therapies, announced today positive results for apceth201 in mouse models for acute graft-versus-host disease (aGvHD).

Tomocube Launches Novel HighResolution Holotomography Microscope

32

Ground-breaking technology unlocks rapid and simple label-free 3D and 4D live cell imaging,A novel optical microscope utilizing diffraction tomography to generate 3D holographic images of unlabelled live cells is now available from Tomocube.

Microbioz India, October 2018 10

ear friends and readers, I hope you would have enjoyed reading our previous issue. Once again, I am delighted to bring for you the new edition of your favourite magazine Microbioz India. It is a “Laboratory Edition” supported by an Interview of Mr. Yogesh Mudras, Managing Director UBM India and other guest articles. While interaction with him we discussed on several topics; For instance, within the realm of the IPW, the CEO Roundtable stands out as one of the most distinguished and successful events. For the last 2 years, the exclusive, closed-door CEO Roundtable has been eminently successful as a strategic gathering of CEOs of the nation’s leading Pharma companies who deep dive into thoughtprovoking discussions on subjects.

Edition also includes a guest post article submitted

by Telstar tilted: Telstar launches Lyogistics Smart R3,New automated inline vial management device able to reject, reintroduce and retrieve vials during loading / unloading process into pharmaceutical freeze-dryers We have the latest market research news and insightful product launches inside collected from worldwide sources to keep you updated with what is going on in the industry.

Dear friends and readers, I hope you find some value in the magazine. Also, I would like to thanks you for being together in the beautiful journey so far. We will wait for your valuable feedback and suggestions as they help us to come up with better content each time. For any further value addition, please write to us at editor@microbiozindia.com.

Interview Report…

reativity and a constant quest to be innovative has been the backbone of the CPhI & P-MEC and the direct reason for its stupendous growth asked by Mr. Yogesh Mudras, Managing Director, UBM in recent interview with Microbioz India magazine for publication in October 2018 issue of the magazine.

About Yogesh Mudras, Managing Director, UBM India Yogesh Mudras leads and manages the entire India operations of UBM plc -- one of the world's leading organiser of dynamic business-tobusiness (B2B) events headquartered in London – especially driving its strategy, business development and key client relationships.

Within just ten years of its inception, UBM India finds itself firmly positioned as the nation’s leading live media and events that engages people and enriches businesses.

At UBM India, Yogesh’s repertoire of businesses is extensive and includes large format B2B exhibitions, conferences, seminars, Business Intelligence, and other properties that serve multiple key markets such as Pharmaceuticals, Jewellery, Security and Homeland Security, Occupational Safety, Children, Baby Care and Maternity, Renewable and Nuclear Energy, Food Ingredients, World of Facilities, Hospitality & Tourism, amongst others.

A seasoned professional with a deep knowledge of the exhibition business, Yogesh was previously Chief Financial Officer (CFO) of the

company for 5 years, before being appointed in his current designation in March 2015. He has driven UBM India’s business with noteworthy acquisitions, much talked about launches, business development and database enhancement, and a refreshed workforce.

His strategic and innovative thinking, an innate understanding of people and the financial and legal ramifications of business decisions, and his passion for the development of India Inc. injects his team with enthusiasm and a strong will to grow organically in these exciting – if uncertain -- times.

Prior to UBM India, Yogesh was associated with VFS Global (part of Swiss-based Kuoni Travels) in the travel & tourism sector where he was the Assistant Vice President, Finance, and was instrumental in successfully negotiating the global visa outsourcing contract of the UK Government’s Foreign & Commonwealth

Microbioz India, October 2018 14

Interview Report…

Office which established VFS’s presence in 42 countries across the globe.

Previously, Yogesh has had fruitful and insightful stints in the shipping industry, heading Finance for Western India for the Japanese shipping major, Mitsui OSK Lines as well as the Shipping Corporation of India, the biggest shipping company in India, where he started his corporate career in 1998, and was responsible for the creation of annual financial statements, audits & automation of systems & processes.

Yogesh is a qualified Chartered Accountant & a Certified Public Accountant (USA) He is a Law Graduate and a Bachelors of Commerce from Mumbai University, besides additionally completing a Business Leadership Programme from the Duke University (USA). He is an Associate Member of Insurance Institute of India, specialising in Marine Insurance & a certified ISO 9001 auditor.

Yogesh is an ardent sports follower and a fitness aficionado who loves to hone his competitive spirit by swimming and playing tennis regularly.

Here are few questions and answers of interaction with Yogesh sir.

How would you choose the venue/location for an event? What are your priorities after choosing the venue/location?

The choice of venue and location depends on a fine-tuned strategy that factors in the reputation and magnitude of the show, the major markets for the range of products on exhibit, the governmental policies surrounding the subject of the expo and several other direct and indirect factors. In the case of our flagship engagement platform, the CPhI &P-MEC India, it has grown to become one of the world’s leading pharmaceutical networking event. Ever since its 10th anniversary in India, the show has become an intrinsic part of the much feted India Pharma Week (IPW), which is a week-long celebration of India’s pharmaceutical industry. The IPW is widely publicised on a national and international scale and annually brings together more than 70,000 attendees including domestic policy makers and global experts from over 125 countries. Industry experts recognise it as a

prodigious show that fosters domestic and international alliances, research, policy and futuristic innovations.

In Mumbai, the expo had started being organized in the two venues of the Bombay Exhibition Centre, Goregaon as well as the MMRDA Grounds, Bandra Kurla Complex.

However, given the stupendous growth of the show, the infrastructural challenges in Mumbai were making it impossible to host a show of the stature and size of CPhI & P-MEC what with traffic directives, and venues being unavailable due to Metro and Bullet train work. Travel logistics aside, we felt it would be extremely beneficial to have a bigger, consolidated venue that offered the entire spectacle under one umbrella. Accordingly, from this year, the IPW will be held from 9th -14th December, 2018 (with the CPhI & P-MEC expo being held from 12th to 14th December) at the India Expo Centre, Greater Noida to create grander business experiences. Besides, being in close geographical proximity to policy makers, consulates and government bodies, the show is poised to enhance the industry’s community building efforts. Just to give an idea, while the Mumbai locations had a combined of 80,000 sqm, the new location has an availability of 235,000 sqm.

Tell me about how has this project (CPHI) has forced you to be innovative & creative.

Creativity and a constant quest to be innovative has been the backbone of the show and the direct reason for its stupendous growth. From its initial days, the CPhI & P-MEC India, geolocated from the global CPhI & P-MEC brand, was a force to reckon with, and its contribution to the growth of the Indian Pharma industry has been second to none.

However, over the years, we recognised that we had reached a saturation point that was beginning to limit the potential of the show.

Being a wall bound expo, we could not accommodate new exhibitors as there was no scope for expansion of space at the current venue. Consequently, the waiting list of new exhibitors kept growing longer with each passing year. Besides, the wall bound situation and the current venue also posed sponsorship related challenges. On the occasion of CPhI

Microbioz India, October 2018 16

Interview Report…

India’s 10th Anniversary, we decided to do something special for all our stakeholders who have been with us throughout this journey and break free from the wall bound situation. The grand India Pharma Week was introduced, celebrating ten years of success in one week of glory at multiple venues. Through it, we offered attendees a mutli-faceted pharma festival offering a range of platforms to cater to various requirements- Business, Leadership, Knowledge, Innovation, Recognition & Networking. Some of the special highlights included the Pharma

Connect Congress, CPhI & P-MEC expo, CEO Roundtable, Pharma Leaders’ Golf, Factory Visit, The India Pharma Awards, and Women Leaders in Pharma. These different facets also synergised with key governmental initiatives like Make in India, Start Up India, Skill India, and act as a catalyst to raise the bar further for the nation as a global engine for the sector.

This year, the third edition of the week-long India Pharma Week will be held this year at India Expo Mart, Greater Noida. An elite congress such as the one we have at the IPW deserves superlative infrastructure and facilities that we are confident the chosen venue will impart. We are sure the move will prove truly

beneficial and convenient for the vast magnitude of exhibitors and visitors as they will get to experience the show and all its verticals under a single roof without needing to factor in the travel and meeting logistics that the previous locations had posed. The entire shift has posed a lot of creative and logistic challenges which the team has risen to, extremely efficiently.

What would be your thought regarding the implementation of GST and change of location from Mumbai to Noida, Delhi, in the market and how it would impact CPhI and P-mec The implement ation of the GST has not made any impact on CPhI & PMEC expo per se. The pharma industry is one of the most organized industry and the GST seems to have been seamlessly adopted in the sector.

Besides, many pharma companiess focus equally on export markets, making the impact lower.

As mentioned previously, the sheer size and world class facilities is bound to help the magnum opus further develop and nurture a complete pharma ecosystem in the sectoral pockets of the North, along with growing the show globally and nationallly. Besides, one cannot overlook the fact that the Delhi-NCR region is becoming the powerhub of the country, and the proximity to the power epicenter helps further the cause and mission of the expo.

Microbioz India, October 2018 18

Interview Report…

The region is also the hub of consulates in India, besides affording seamless connectivity to the commercial capitals around the world.

What new will be offered at this year’s India Pharma Week?

With every edition of the IPW, we are keen to push the national agenda forward and break new frontiers, while offering our attendees the much loved regular features.

For instance, within the realm of the IPW, the CEO Roundtable stands out as one of the most distinguished and successful events. For the last 2 years, the exclusive, closed-door CEO Roundtable has been eminently successful as a strategic gathering of CEOs of the nation’s leading Pharma companies who deep dive into thought-provoking discussions on subjects. The recommendations from elite thought leaders results in a White Paper Report that is presented to policy makers and the power corridors of the nation.This year, we move forward the country’s agenda of Making India an uncontested Pharma Supergiant for the first time, to international shores, at CPhI Worldwide, in Madrid where eminent CEOs from the industry will participate in Discussion 1: ‘The Global Perspective’. This will subsequently be followed by Discussion 2: ‘National Perspective’ at the India Pharma Week in Greater Noida.

Both the discussions will form an integral part of the 3rd edition of the CEO Roundtable.

Again, while India is renowned as the pharmacy hub of the world, and the Indian pharma economy lauded for its rapid growth, the industry is at a very crucial juncture in its growth trajectory. Certain challenges continue to surround it including a shortage of highly skilled talent. This year, we are shining the spotlight and handpicking young talent with a Paper presentation whereby a well-renowned jury panel picks top post graduate students to present their thesis on the pharma industry, and the winners will be feted during the Awards night. Besides, we also have included a special Masterclass, a new feature of the IPW, that will comprise prominent speakers from top organizations in a platform for knowledge sharing.

What makes CPhI and P-mec different from other trade fairs?

CPhI &P-MEC is UBM’s flagship engagement platform, and the world’s leading Pharmaceutical networking event.

The show is the epitome of India’s strength in the Pharma industry and has consistently grown to serve as an exclusive congregation of key global players across the pharmaceutical sector.

CPhI & P-Mec India 2018 is expected to witness a record participation of 1523 exhibitors from 26 countries, spread over an area of 75,000 sq metre. As mentioned earlier, with the introduction of the India Pharma Week, we succeeded in bringing about an unparalleled thought leadership, community building and knowledge sharing experience that stands out from any other fair.By organising such a signature show in India, the CPhi-PMEC under the aegis of the India Pharma Week firmly establishes the country as an impressive hub and global destination for the sector. The show is also widely publicised on a national and international scale.

Microbioz India, October 2018 20

Guest Post‌

Telstar launches Lyogistics Smart R3 New automated inline vial management device able to reject, reintroduce and retrieve vials during loading / unloading process into pharmaceutical freeze-dryers

N

ďƒ˜ ďƒ˜

Operated by a screw mechanism, without elements over the vials, the compact versatile system ensures the cleanliness and asepsis in the work zone The integration of the vial retrieving smart function for samples in freeze-drying process opens up a new pioneering field for pharmaceutical research

Terrassa (Barcelona) 2018, October 19th. The purpose of the innovative inline vial management device developed by Telstar is to reject, retrieve for sampling, or reintroduce vials automatically during loading / unloading process into pharmaceutical freeze-dryers.

Under the brand of Lyogistics Smart R3, the new system has been designed for automatic detection & treatment of vials in an automatic line.

The new compact inline quality control unit needs to be fully integrated in automatic loading & unloading systems in order to automatically manage the paths of vials during the loading and/or the unloading of freeze dryers.

Designed for detection and the subsequent management of a particular vial in the process line, the module is able to identify and separate a specific vial according to different parameters: stopper position, missing stopper, wrong stopper position, color variation, etc. After identification, it is capable of performing several tasks: rejection of the vial to a rejection

container, separation of vial for sampling, separation of one vial for a specific function, introduction of a pre-prepared vial or reintroduction of a vial subsequent to removal.

The system integrates several mechanisms ensuring appropriate processing of lyophilized products as well as reducing the risk of batch contamination, spoilage and the time of operator intervention. Vials are transported by conveyors and screws without pushers, neither bellows nor mechanisms in contact with product, which allows the module to work in an open system without concealed parts guaranteeing cleanliness and greater performance.

In addition, the compact module is featured by a diaphanous nature, unobstructed and clear. No racks, belts, or linkages occupy the work area and all mechanisms are under the base plate or closed. The compact and versatile solution, which has been conceived for management at high process speeds of up to 600

Microbioz India,October 2018 22

vials per minute, is compatible with cold

Guest Post‌

sterilization methods as Hydrogen Peroxide and offers easy integration with RABS and isolators.

The versatile module has been configured to be integrated to industrial-scale single-side or passthrough freeze-dryers and the vial detection/sampling system will work according to the freeze-dryers features, only inlet side, inlet and outlet side (same side) and inlet and oultlet side (opposite side).

Lyogistics Smart R3, in which the three main functions (rejecting, reintroducing & retrieving) are behind the naming concept, is a result of Telstar’s continuous innovation process.

In fact, this version enhances the unit presented by the company in 2015 doubling the maximum speed of vials and reducing the footprint, as well as the amount of change parts when different vial formats need to be used.

For more information: TELSTAR Phone: +34 93 736 16 00 Website: www.telstar.com E-mail: marketing@telstar.com

Business News…

Apceth Biopharma Presents Positive Data Demonstrating Efficacy of apceth-201 in Preclinial Models of Acute GvHD Munich, Germany, October 19, 2018 / B3C newswire / -- apceth Biopharma GmbH, a company with the mission of improving patients’ lives with next generation cell therapies, announced today positive results for apceth-201 in mouse models for acute graftversus-host disease (aGvHD). The data was highlighted in a poster presentation at the Annual Congress of the European Society of Gene and Cell Therapy in Lausanne on October 16-19.

“We are very excited with these results that clearly show the transformative therapeutic potential of apceth-201 in an immune-mediated disease with high unmet medical need and few treatment options”, said Dr Christine Guenther, CEO of apceth Biopharma.

“Based on these promising and impressive data, we are currently preparing to initiate a phase 1/2 clinical study assessing the safety and efficacy of apceth-201 in adult steroid-refractory GvHD patients.” Acute graft-versus-host disease is a frequent complication associated with allogeneic hematopoietic stem cell transplantation (HSCT).

Immunosuppressants are used to manage aGvHD; however, steroid-refractory aGvHD develops in many cases and has an extremely poor prognosis. apceth-201 significantly improved clinical score and overall survival in two aGvHD models apceth-201 are allogeneic human mesenchymal stromal cells (MSCs) that have been genetically modified to express alpha-1 antitrypsin (AAT), a protease inhibitor exerting potent anti-

inflammatory and tissue-protective functions to further augment the immunomodulatory potential of MSCs. In vitro assays demonstrated that apceth-201 efficiently suppresses T-cell proliferation, the maturation of dendritic cells, and also polarizes macrophages to an antiinflammatory M2 type. The in vivo efficacy of apceth-201 was assessed in two different mouse models for aGvHD. In a humanized model vehicle-treated control animals succumbed quickly to GvHD, whereas median survival was doubled in apceth-201-treated animals. Mice receiving apceth-201 showed significantly improved clinical scores, a striking amelioration of bone marrow cellularity, and reduced levels of inflammatory markers. apceth-201 was further tested in a GvHD model system which closely mimics haploidentical HSCT. Vehicletreated control animals again succumbed quickly to GvHD, whereas treatment with apceth-201 resulted in long-term survival of 57 % of the mice. Initially, all apceth-201-treated animals exhibited clinical scores comparable to the control animals. However, within a period of 25 days after the second cell injection, the clinical scores had returned to baseline, indicating complete resolution of GvHD. This promising data has led to planning of a phase 1/2 study using apceth-201 for the treatment of steroidrefractory aGvHD in adults.

About GmbH

apceth

Biopharma

Apceth Biopharma is a pioneering company in cell therapies and regenerative medicine with an innovative portfolio of drug candidates for the treatment of inflammation, autoimmunity and solid tumors. apceth is developing two proprietary next generation gene therapy products, which are based on the introduction of therapeutic transgenes into mesenchymal stem cells (MSCs).

Microbioz India, October 2018 26

Business News…

apceth-201 expresses the immunomodulatory protein alpha-1 antitrypsin for the treatment of graft-versus-host disease. The company’s second program, apceth-301, expresses a potent immunostimulatory “cocktail” of cytokines, which locally activates the immune system to eradicate tumor cells. apceth-301 is currently being developed for glioblastoma as well as for other solid tumors. apceth Biopharma is also a leading and certified Contract Development and Manufacturing Organization for cell and gene therapeutics with a broad international customer base. apceth owns state-of-the-art manufacturing facilities with Grade B/A, C and D cleanrooms (ISO 5, ISO 7, ISO 8, BSL2) and is certified according to regulatory requirements for cell and gene therapies (Advanced Therapy Medicinal Products, ATMPs). The company has a comprehensive expertise in GMP manufacturing of autologous and allogeneic cell types that are either native or genetically modified. It has longstanding experience with various cell products, including mesenchymal stem cells (MSCs),

efficient and fast supply for patients all over the continent.

Contact Apceth Biopharma GmbH Dr Christine Guenther, CEO Max-Lebsche-Platz 30 81377 Munich Germany +49 (0)89 7009608 0 contact@apceth.com www.apceth.com

Novartis' canakinumab gets an FDA rejection, but it raises guidance anyway Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target— at least not in the cardiovascular sales department.

The Swiss drugmaker said Thursday that the FDA had rejected canakinumab—already marketed as Ilaris for patients with rare inflammatory diseases—as a treatment for certain patients who have had a prior heart attack. The agency requested additional data on

hematopoietic stem cells (HSC), lymphocytes, monocytes, dendritic cells, cord blood derived stem cells, and has the potential to expand to CAR-T and induced pluripotent stem cell (iPSC) technologies. apceth has successfully obtained manufacturin g licenses for multiple cell therapy products for clinical as well as commercial use. apceth’s CDMO team provides fully customized solutions in the development Cell therapy, gene therapy and now radioactive therapy Novartis is piecing together its and path for future growth under new CEO Vas Narasimhan. (Novartis) production of every the responder population, executives said on the customer product and process. Located centrally company's third-quarter conference call. in the heart of Europe, apceth can perform

Microbioz India, October 2018 28

Business News…

Prospects for canakinumab had been iffy since last August, when the prospect showed it could cut the risk of major CV events by 15% and cardiovascular death by 10%—figures that likely wouldn't prove "fully compelling to payers." But the Swiss drugmaker identified a subpopulation in which it could make a stronger case.

The regulatory setback wasn't the only bad news for Novartis on Thursday; its third-quarter sales also came in slightly below analyst expectations.

But that didn't stop the pharma giant from dialing up its full-year sales outlook.

Unsurprisingly, generics unit Sandoz’s lag pulled back Novartis’ sales growth in the quarter by 6% at constant currencies to $12.78 billion, missing the consensus mark by less than 1%. But Novartis is now projecting sales to grow by a mid-single digit percentage, up from the previous low- to mid- single-digit rate.

Why the rosier outlook? Anti-inflammatory drug Cosentyx and heart failure treatment Entresto are delivering. For the third quarter, both drugs beat analyst expectations.

It wasn't all that long ago—think this year's first quarter—that Cosentyx came in significantly below estimates. Management in April blamed rebates the company had to offer to win prescriptions in previously untreated patients. Fast forward to Q3, and sales grew 37% year over year to reach $750 million. The drug also surpassed AbbVie best-seller Humira in total U.S. prescriptions in its psoriatic arthritis indication, CEO Vas Narasimhan said on the call.

The IL-17A inhibitor is up against some new competition of its own, though, such as Johnson & Johnson IL-23 inhibitor Tremfya. Looking to seal its lead, Novartis in May started a head-tohead trial against Tremfya in patients with psoriatic plaques resistant to J&J sister drug Stelara, with results expected to hit in 2019. In the meantime, Novartis last month unveiled five-year real-world evidence demonstrating Cosentyx’s ability to improve quality of life.

Entresto, meanwhile, has been performing well since 2017, and in the third quarter, sales again shot upward to $271 million, compared with the $239 million it posted in the second quarter.

Recent data also showed the drug can be initiated safely in hospitalized patients shortly after an acute heart failure episode.

Novartis is working reinvent itself as a “medicines company” under new leader Narasimhan. It's in the process of spinning off Alcon and just recently sold off a big chunk of struggling Sandoz to India’s Aurobindo Pharma, leaving behind only some complex generics and biosimilars. Earlier in the year, it sold its stake in its consumer health joint venture to partner GlaxoSmithKline, too. And it’s also embarking on a massive restructuring announced last month, which will see it slash its workforce by about 19%.

On the call, Narasimhan laid out a blueprint for the future. In cell therapy, the company has new CAR-T treatment Kymriah; in gene therapy, it just bought AveXis for $8.7 billion and gained control of its lead candidate, spinal muscular atrophy therapy AVXS-101.

And on Thursday, Novartis boosted its bet on radioactive therapy with a $2.1 billion deal agreement for Endocyte. That buy will build on Novartis’ existing radiopharma business from Lutathera, approved for a type of cancer that affects the pancreas or gastrointestinal tract.

In what Narasimhan described as a strong launch with “blockbuster potential,” Lutathera has been given to over 1,100 patients in the U.S. since its FDA approval late January, with sales climbing to $56 million in the third quarter.

Story source/Credit: The story is collected from fiercepharma and authored by: Angus Liu

Microbioz India,October 2018 30

Product Launch…

Tomocube Launches Novel High-Resolution Holotomography Microscope Ground-breaking technology unlocks rapid and simple label-free 3D and 4D live cell imaging A novel optical microscope utilizing diffraction tomography to generate 3D holographic images of unlabelled live cells is now available from Tomocube. Called HT-1, the new microscope delivers quantitative nanoscale, real-time, dynamic images of individual living cells quickly and simply without any sample preparation.

The holotomography images also deliver vital information on unique cell properties, including cell volume, shapes of sub-cellular organelles, cytoplasmic density, surface area, and deformability. The simplicity of operation and elimination of any preparative requirement will allow more researchers and clinicians to quantitatively study cell pathophysiology and the efficacy of drug treatments.

“Unlike expensive atomic force, electron and laser-scanning light microscopes that require extensive sample preparation and/or labelling, the HT-1’s 3D imaging technology relies on the same fundamental property of light as traditional phase contrast microscopes,” says Aubrey Lambert, Tomocube’s Chief Marketing Officer. “When light passes through any object, a phase shift is observable depending on its refractive index (RI). If this emergent light is viewed together with the original light,

brightness changes can be seen dependent on the degree of phase shift. In the Tomocube microscope, a 3D image, or tomogram, is created from the RI measured at each 3dimensonal location during a 360-degree rotation. A similar concept using X-rays and nuclear magnetic moments is found in CT and MRI scanners.”

At the heart of the HT-1 is a complex digital micromirror device (DMD) optical light shaper, consisting of several hundred thousand micromirrors arranged in a rectangular array.

Each individual mirror can be tilted plus or minus 12 degrees and the use of the DMD eliminates the need for moving parts in the lightpath. This patented technology allows the HT-1 to set its control beam rotation and rapidly switch its illumination angle to generate the 3D RI tomogram of the sample.

All the functions of the HT-1 are controlled by the TomoStudio software suite. A flexible user interface provides fast imaging capability and 2D/3D/4D visualization of the cellular images based on 3D RI distributions of the cells and tissues.

According the Lambert, “Cellular analysis plays a crucial role in a wide variety of research and diagnostic activities in the life sciences although the information available is limited by current

Microbioz India, October 2018 32

Product Launch…

microscopy techniques. The Tomocube HT-1 overcomes many of these limitations and open new vistas for researchers and clinicians to understand, diagnose and treat human diseases.”

For more information: http://www.tomocube.com/

Scientists Develop Recombinant Human Antibody Panel against Snake Venom Collaboration between IONTAS, Cambridge, Instituto Clodomiro Picado (Universidad de Costa Rica), and Technical University of Denmark to develop fully human IgG antibodies that neutralise black mamba snake venom in vivo IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has announced a collaborative paper published in Nature Communications with the Technical University of Denmark, and the Instituto Clodomiro Picado of the University of Costa Rica describing the development of a panel of human antibodies that neutralise elements of black mamba snake toxin in an in vivo model.Each year, around two million people fall victim to snakebite envenoming, which leads to more than 100,000 deaths and approximately 400,000 cases of severe sequalae, such as amputation. Particularly, impoverished victims living in snake-infested areas of the tropics are at risk, and many bites are left untreated due to the unavailability of safe and effective antivenoms. Snakebite envenoming has recently been introduced on the World Health Organization’s list of neglected tropical diseases due to its high disease burden.

The “proof of concept” research described in Nature Communications identified key components, including dendrotoxins, in the black mamba’s venom which contribute to venom toxicity. Human antibodies were generated to these dendrotoxins using IONTAS Phage Display Technology and cocktails of IgG-

formatted human antibodies were then shown to protect mice from dendrotoxin-mediated neurotoxicity in vivo.

Associate Professor Andreas HougaardLaustsen, Technical University of Denmark, commented: “Current antivenoms are based on plasma-derived animal antibodies, which are effective in neutralising venom toxicity, but are also associated with serious adverse reactions, such as serum sickness, due to their non-human origin. With our work we have laid the first stone on the technological path towards the manufacture of a next-generation fully human antivenom, devoid of such drawbacks.”

Professor José María Gutiérrez, Instituto Clodomiro Picado, Universidad de Costa Rica, said: “It is rewarding to see that classic techniques in toxinology and state-of-the-art methodologies of recombinant DNA could be successfully combined to demonstrate clear therapeutic potential. This recombinant antibody approach opens the door to the development of novel tools in the treatment of snakebites.”

Dr John McCafferty, Founder and CEO, IONTAS said: “Snake envenomation is a particular burden among the world’s poorest people and the approach to treatment, based on poorly defined animal serum has not changed in decades. IONTAS were motivated to contribute our resources and experience in recombinant antibody technology towards this initial proofof-concept study. We hope that this report will help encourage funders to support the scientific community and advance the treatment of snakebites using modern antibody engineering methods.

Although many challenges remain in the development of safe, efficacious and costeffective drug cocktails, it is an achievable goal with the ultimate reward of seeing science help improve human lives.”

For more information: https://www.iontas.co.uk/

Microbioz India, October 2018 34

Product Launch…

Priorclave Launches New Autoclave Developments at Medica 2018leadings autoclave One of Britain’s manufacturers, Priorclave, is taking the opportunity to unveil new technological advances to its range of laboratory and research grade autoclave designs and performance on stand D06-7 (Hall 3A) at this year’s Medica exhibition.

Priorclave will be showing its QCS 100 litre front-loading autoclave. It will be fitted with TACTROL® 3, this incorporates the very latest advances in microprocessor controls and BEE LIVE which gives the autoclave Wi-Fi

connectivity and which will be demonstrated in real time.

TACTROL® 3 is a new generation of controllers with a crystal clear user interface LCD display and presents simplistic setting functions. A quick-view menu shows all the functions that have been set on any select program. Once the screen has been accessed by pressing the ‘OK’ button settings can be easily

altered using left and right arrows. Through the quick-view menu lab staff also can enable or disable Loadsense, freesteam, media warming, delayed start and vacuum settings.

For environments where pre-programs need to be tamperproof Priorclave has incorporated full setting security managed with passcodes and a manual key-switch.

The other key development to be seen for the first time at any time is Bee Live, a system bringing Wi-Fi connectivity to the entire range of Priorclave laboratory autoclaves and research sterilisers. It provides immediate connectivity to a variety of Wi-Fi enabled devices such as Smart phones, tablets, iPads and laptops, enabling lab staff to remotely monitor sterilising parameters.

The company will be running a live demonstration throughout the Medica exhibition on stand D06-7 (hall 3), with automatic data transferred from the QCS front loading and a remotely sited smart tablet.

Whether for use in research or general laboratory applications, the performance and build quality of the Priorclave QCS range of front loading autoclaves has made it a global success. The QCS EH100, a 100 litre laboratory autoclaves to be shown is part of the company’s most popular range QCS range which offers exceptional load capacity combined with superior sterilising performance. Visitors to the Priorclave stand will be able to examine the build-quality first hand.

For more information: https://www.priorclave.co.uk/

SpeedVac Vacuum Concentrators Now Offer Preset and Custom-Made Programs for Optimal Application Flexibility The Thermo Scientific Savant SpeedVac systems achieve fast, one-click solvent evaporation.

Chemists, chromatographers and molecular biologists can now benefit from the first-ever

Microbioz India, October 2018 36

Product Launch…

line of vacuum concentrators offering a library of pre-programmed protocols, while also allowing users to create custom programs, for fast and reliable evaporation of a broad range of solvents.

Built on Thermo Fisher’s leading vacuum concentration technology, the upgraded Thermo Scientific Savant SpeedVac systems provide users with the flexibility to choose from a selection of preset or custom-made programs to suit varying application needs.

Like their predecessors, the new vacuum concentrators achieve a reduced drying time and are compatible with a large number of solvents, helping to boost laboratory efficiency and productivity across a wide array of pharmaceutical, biotechnology, academic research, industrial, agricultural and food testing applications. The Savant SpeedVac line of products consists of eight vacuum concentrators, ranging from a compact, integrated device designed for low-volume sample preparation, to medium-capacity models available in either integrated or modular designs, to large, modular systems addressing highvolume sample preparation needs.

"For decades, the Savant SpeedVac vacuum concentrators have helped scientists accelerate solvent evaporation as part of the sample preparation process, facilitating developments in genomics, chromatography and chemistry," said Amit Agarwal, vice president and general manager of water and lab products, Thermo Fisher Scientific.

"The new systems have been upgraded with a choice of storable programs, which help automate the dry-down process, allowing for walk-away operation and optimal peace of mind."

The Savant SpeedVac portfolio includes: Model DNA130 – A compact, integrated system designed for low-volume preparation of samples, including nucleic acids, polymerase chain reaction (PCR) preps and synthetic oligonucleotides, to support DNA and RNA applications.

Model SPD120 – A medium-capacity, modular system, which is resistant to aggressive solvents used in DNA and biological applications, such as methanol and acetonitrile w/0.1% trifluoroacetic acid (TFA). It is also suitable for applications where freeze-drying or lyophilization is needed.

Model SPD130DLX – A medium-capacity, modular system, which is resistant to aggressive solvents used in combinatorial chemistry applications, including TFA and dimethyl sulfoxide (DMSO).

Model SPD140DDA – A medium-capacity, modular system, used for drying aggressive organic solvents, strong acids, bases and combinatorial chemistry solvents.

Models SDP1030 and SDP2030 – Mediumcapacity, fully integrated systems, combining a concentrator, a refrigerated cold trap, a diaphragm pump and a vacuum gauge in a single, compact unit.

Model SPD210 – A large-capacity, modular system, suitable for drying aqueous and organic solvents in large sample volumes.

Model SPD300DDA – A large-capacity, modular system, used for drying aggressive organic solvents, strong acids, bases and combinatorial chemistry solvents in large sample volumes.

For more information: https://www.thermofisher.com/in/en/home.ht ml

Microbioz India, October 2018

38

Product Launch…

New Single Quadrupole Mass Spectrometry Technology Designed for Chromatographers Performing LC-MS Routine Analysis Thermo Scientific ISQ EM system offers a robust, easy-to-use and reliable solution for both novice and expert usersChromatographers looking for bold confidence in their samples can now benefit from a single quadrupole mass spectrometer designed for ease-of-use while offering application flexibility and reliable results for challenging mass confirmation analyses.

Driven by industry demand for a robust, easy to implement system, Thermo Fisher Scientific designed the Thermo Scientific ISQ EM single quadrupole mass spectrometer for high performance and productivity standards in laboratories. With a mass range of 10–2000 m/z, the system offers the power to detect and quantify small and large molecules, and supports analytical needs across an extensive range of applications – from drug development to manufacturing support and quality control. The system’s high-performing heated electrospray ionization (HESI) and dual HESI/atmospheric

pressure chemical ionization (APCI) probes facilitate the measurement of polar and nonpolar analytes, enabling application flexibility.

"Liquid chromatography users have been struggling with the inherent perceived complexities of mass spectrometry technology as they use LC-MS to routinely analyze samples," said Fabrizio Moltoni, vice president and general manager, High-Performance Liquid Chromatography (HPLC), Thermo Fisher Scientific. "With this top of mind, we designed the ISQ EM to enable novice and expert mass spectrometry users to take advantage of the technique’s excellent sensitivity and selectivity for the rapid and reliable analysis of complex sample matrices."

"We’ve long been looking for a single quadrupole mass spectrometer that could allow us to obtain substantial information from routine samples, and thereby permits single assay runs, reliably tracks emerging impurities and quickly confirms the mass of newly synthesized entities," said Lydia Sweet, senior analytical chemist, Sachem, Inc. "The new ISQ EM addresses all of these needs, while being easy-to-use for the scientists in our lab."

The ISQ EM is integrated with HPLC systems and fully controlled by Thermo Scientific Chromeleon Chromatography Data System (CDS), which offers tools to guide users through LC-MS method development and select appropriate source conditions. Thermo Scientific Chromeleon XPS Open Access software also supports the ISQ EM with walkup workflows for simple daily operation.

Additionally, full integration with native control in Chromeleon CDS enables users to benefit from the entire productivity suite, from method creation through final reporting. A built-in reference standard also automates instrument calibration for a user-friendly experience.

Thermo Fisher is showcased the new instrument at the 32nd International Symposium on Chromatography (ISC) 2018 at Booth #16, the Congress and Exhibition Centre, CannesMandelieu, France, September 23–27.

The introduction of the ISQ EM further expands the product portfolio introduced in 2017 with the launch of the Thermo Scientific ISQ EC single quadrupole mass spectrometer.

Microbioz India, October 2018

40

Product Launch‌ The ISQ EC was designed to integrate with both ion chromatography and liquid chromatography systems and deliver lowmolecular-weight performance for the detection and quantification of ions with limits of

detection in the single-digit-parts-per-billion range.

For more information: https://www.thermofisher.com/in/en/home.ht ml

Automatic Tissue Processor by York Scientific Industries Pvt. Ltd.

arrangement provided for easy viewing also prevents unauthorised tampering of timing cycle. Tissues are subjected to continuous agitation by rotating S.S. Tissue basket for thorough penetration of reagents.

Glass door with lock and key arrangement provided for easy viewing also prevents unauthorised tampering of timing cycle. Tissues are subjected to continuous agitation by rotating S.S. Tissue basket for thorough penetration of reagents.

An automatic adjustable delay start is another standard feature.

Thermostatically controlled Stainless Steel.

York Scientific Industries Pvt. Ltd. Delhi India based company whose registered trade mark is is a manufacturer, supplier, and exporter of Medical, Laboratory and Research Equipment to the Healthcare Sector.

About product: A compact, sturdy and very reliable instrument designed with latest technology for complete automatic dehydration and filtration of human, animal and plant tissues, up to final fixing in wax.

Pre-programmable provision for dehydration cycle (user selectable) is a standard feature. Glass door with lock and key

Wax bath maintains temperature throughout the process.

For more Information: Please contact: Email ID: ysipl@yorco.co.in

RNI NUMBER: UPENG/2017/73675